Development and Evaluation of SARS- CoV-2 RNA Polymerase Inhibitors
- Funded by Canadian Institutes of Health Research (CIHR)
- Total publications:2 publications
Grant number: 170343
Grant search
Key facts
Disease
COVID-19Known Financial Commitments (USD)
$502,766.41Funder
Canadian Institutes of Health Research (CIHR)Principal Investigator
PendingResearch Location
CanadaLead Research Institution
University of AlbertaResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Coronaviruses (CoV) can cause severe human respiratory diseases, which is documented by three major outbreaks over the past 17 years: SARS-CoV in 2003, MERS-CoV in 2011, and currently SARS-CoV-2. In response to the current COVID-19 outbreak caused by SARS-CoV-2, we oppose to develop novel tools to discover, develop and evaluate inhibitors of the viral polymerase. The polymerase is an enzyme that is essentially required for the propagation of SARS-CoV-2, which makes it an attractive target for therapeutic intervention strategies.
Publicationslinked via Europe PMC
Last Updated:a day ago
View all publications at Europe PMC